Literature DB >> 29211324

Non-invasive prenatal testing for fetal inheritance of maternal β-thalassaemia mutations using targeted sequencing and relative mutation dosage: a feasibility study.

L Xiong1,2, A N Barrett1, R Hua2, Ssy Ho3, L Jun1, Kca Chan4, Z Mei2, M Choolani1.   

Abstract

OBJECTIVE: To evaluate whether targeted sequencing and relative mutation dosage can be used to diagnose correctly inheritance of maternal β-thalassaemia mutations in cell-free DNA.
DESIGN: Feasibility study using samples collected in a prenatal clinic.
SETTING: South East Asia. POPULATION: Couples where both partners were known to be carriers of one of four common β-thalassaemia mutations or an HbE mutation, and therefore at risk of carrying a fetus affected with β-thalassaemia.
METHODS: 49 samples previously identified as having inherited a paternal β-thalassaemia mutation were amplified using nested polymerase chain reaction (PCR), and then sequencing. Relative mutation dosage was used to classify the fetus as having inherited the wild-type or mutant maternal allele. MAIN OUTCOME MEASURES: Classification of the fetus as 'unaffected' (if the maternal wild-type allele was inherited) or 'affected' with β-thalassaemia (if the maternal mutant allele was inherited).
RESULTS: A classification for inheritance of maternal allele was obtained in 48/49 samples (98.0%). A concordant call was made in 44/48 cases (91.7%): one false-positive and three false-negatives were obtained. Thus, we had an overall sensitivity of 87.5% [95% confidence interval (CI) 67.6-97.3%] and a specificity of 95.8% (95% CI 78.9-99.9%) for inheritance of maternal genotype.
CONCLUSIONS: RMD for detection of inheritance of maternal β-thalassaemia mutations has potential for clinical use. Our sequential approach could be applied to other single-gene disorders. TWEETABLE ABSTRACT: NIPT for β-thalassaemia achieved using nested-PCR followed by relative mutation dosage.
© 2017 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  cell-free DNA; non-invasive prenatal diagnosis; relative mutation dosage; β-thalassaemia

Mesh:

Substances:

Year:  2018        PMID: 29211324     DOI: 10.1111/1471-0528.15045

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  5 in total

1.  Identification of a de novo fetal variant in osteogenesis imperfecta by targeted sequencing-based noninvasive prenatal testing.

Authors:  Xiuju Yin; Yang Du; Han Zhang; Zhandong Wang; Juan Wang; Xinxin Fu; Yaoyao Cui; Chongjian Chen; Junbin Liang; Zhaoling Xuan; Xiaohong Zhang
Journal:  J Hum Genet       Date:  2018-08-21       Impact factor: 3.755

2.  Noninvasive prenatal screening test for compound heterozygous beta thalassemia using an amplification refractory mutation system real-time polymerase chain reaction technique.

Authors:  Narutchala Suwannakhon; Tanapat Pangeson; Teerapat Seeratanachot; Khwanruedee Mahingsa; Arunee Pingyod; Wanwipa Bumrungpakdee; Torpong Sanguansermsri
Journal:  Hematol Rep       Date:  2019-09-18

3.  Noninvasive prenatal testing for β-thalassemia by targeted nanopore sequencing combined with relative haplotype dosage (RHDO): a feasibility study.

Authors:  Fuman Jiang; Weiqiang Liu; Longmei Zhang; Yulai Guo; Min Chen; Xiaojing Zeng; Yang Wang; Yufan Li; JiaJia Xian; BoLe Du; Yuhuan Xie; Shuming Ouyang; Sheng Li; Yinghong Yang; Chunsheng Zhang; Fei Luo; Xiaofang Sun
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

4.  Noninvasive prenatal prediction of fetal haplotype with Spearman rank correlation analysis model.

Authors:  Du Hanxiao; Sun Luming; Chen Songchang; Yang Jingmin; Zhang Yueping; Zhang Shuo; Chen Hongyan; Jiang Ning; Lu Daru
Journal:  Mol Genet Genomic Med       Date:  2022-05-29       Impact factor: 2.473

5.  Performance of whole-genome promoter nucleosome profiling of maternal plasma cell-free DNA for prenatal noninvasive prediction of fetal macrosomia: a retrospective nested case-control study in mainland China.

Authors:  Qianwen Lu; Zhiwei Guo; Jun Zhang; Ke Wang; Qi Tian; Siping Liu; Kun Li; Cailing Xu; Caimin Li; Zenglu Lv; Zhigang Zhang; Xuexi Yang; Fang Yang
Journal:  BMC Pregnancy Childbirth       Date:  2022-09-10       Impact factor: 3.105

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.